Daa Retreatment Vosevi denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for daa retreatment vosevi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Vosevi as "Experimental" or "Investigational"

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) carries full FDA approval for its retreatment indication in chronic hepatitis C. An "experimental" or "investigational" denial from Cigna is therefore factually incorrect and highly reversible. These denials occasionally occur when claims are routed to the wrong review pathway, when an older coverage policy predating Vosevi's approval is applied, or when a reviewer conflates Vosevi's use in a specific clinical scenario with off-label use. The rebuttal is documentary: FDA approval and applicable professional society guideline endorsement directly contradict the "experimental" designation.

## Why This Denial Is Appealable

A drug with full FDA approval cannot be legitimately characterized as experimental for its approved indications. Professional society guidelines from AASLD (American Association for the Study of Liver Diseases) and IDSA (Infectious Diseases Society of America) endorse retreatment regimens including Vosevi for patients who have experienced prior DAA failure. Appeals that present the FDA approval documentation alongside relevant guideline endorsement have a strong factual basis.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline on the denial letter. The full-and-fair review standard under ERISA §503 requires Cigna to weigh the documentary evidence you submit.
• External review: Available after a final internal denial. The approximately four-month window runs from the date of the final internal determination. Expedited review (often 72 hours) is available when standard timelines would jeopardize your health — your prescriber should document that urgency.
• Concurrent state complaint: Filing a complaint with your state's insurance department or HHS can apply additional pressure and create a parallel record.

## Concrete Appeal Steps

1. Download the FDA approval documents for Vosevi from Drugs@FDA (approval letter and current prescribing information). 2. Obtain the current AASLD/IDSA HCV Guidance recommendation for retreatment — available at hcvguidelines.org — for your patient's specific prior treatment history and genotype. 3. Have your prescriber write a letter confirming the prescribed use is within the FDA-approved indication and consistent with current professional society guidance. 4. Submit the internal appeal with these materials, explicitly citing FDA approval status and the guideline endorsement. 5. If denied internally, file for external review immediately — the factual record strongly favors the patient.

## Documentation to Gather

• FDA Drugs@FDA printout: Vosevi approval letter and prescribing information
• Current AASLD/IDSA HCV retreatment guidance (print the relevant section)
• Prescriber letter: confirms FDA-approved indication, references guideline support
• Prior DAA treatment and failure documentation: establishes retreatment indication
• Current HCV RNA and genotype data

## Criteria-Mapping Structure

Identify Cigna's specific experimental/investigational definition from its coverage policy (request a copy). List each element of that definition in column one. In column two, cite the documentary evidence that shows the element is not met: FDA approval date, labeling section, and guideline citation. Dismantling each element of the definition individually leaves no ground for sustaining the denial.